Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.235 USD | +5.37% | -0.31% | -45.27% |
04-04 | Morgan Stanley Initiates Coverage on Mural Oncology With Overweight Rating, $13 Price Target | MT |
01-08 | Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 51.96M 4.11B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 156M 12.38B | Net cash position 2025 * | 196M 15.52B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 119 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.62% |
1 day | -4.95% | ||
1 week | -4.95% | ||
Current month | -8.63% | ||
1 month | -14.48% | ||
3 months | -31.63% | ||
6 months | -39.69% | ||
Current year | -48.14% |
Date | Price | Change | Volume |
---|---|---|---|
27/06/24 | 3.24 | +5.54% | 106 022 |
26/06/24 | 3.07 | -4.95% | 222,412 |
25/06/24 | 3.23 | +0.31% | 138,858 |
24/06/24 | 3.22 | -0.62% | 202,714 |
21/06/24 | 3.24 | -0.31% | 398,975 |
Delayed Quote Nasdaq, June 26, 2024 at 09:00 pm
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-48.14% | 51.96M | |
+16.49% | 122B | |
+21.73% | 115B | |
+22.45% | 26.64B | |
-21.81% | 19.91B | |
-16.75% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- MURA Stock